Fig. 4
From: The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer
The effect of pharmacological inhibition of Cav3.2 on trastuzumab-resistance. a Cells were treated with mibefradil (0.01–1 µM) alone or with trastuzumab (10 µg/mL) 24 h after seeding for 192 h (n = 3 ± SD). Mibefradil did not promote the response to trastuzumab (p > 0.05). b Cells were treated with ML218 (0.1–10 µM) alone or with trastuzumab (10 µg/mL) 24 h after seeding for 192 h (n = 3 ± SD). ML218 did not promote the response to trastuzumab (p > 0.05). Statistical analyses were performed using two-way ANOVA with Bonferroni post-tests